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Abstract
Cancer remains the second leading cause of death after heart disease in the US. While
metastasized cancers such as breast, prostate, and colon are incurable, before their distant spread,
these diseases will have invaded the lymphatic system as a first step in their progression. Hence,
proper evaluation of the disease state of the lymphatics which drain a tumor site is crucial to
staging and the formation of a treatment plan. Current lymphatic imaging modalities with visible
dyes and radionucleotide tracers offer limited sensitivity and poor resolution; however, newer
tools using nanocarriers, quantum dots, and magnetic resonance imaging promise to vastly
improve the staging of lymphatic spread without needless biopsies. Concurrent with the
improvement of lymphatic imaging agents, has been the development of drug carriers that can
localize chemotherapy to the lymphatic system, thus improving the treatment of localized disease
while minimizing the exposure of healthy organs to cytotoxic drugs. This review will focus on the
use of various nanoparticulate and polymeric systems that have been developed for imaging and
drug delivery to the lymph system, how these new devices improve upon current technologies, and
where further improvement is needed.
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1. Introduction
The lymphatic system is a complex network of nodes, vessels and thin-walled capillaries
that drain the protein-rich lymph, excess fluids, and waste products from the extracellular
space within most organs to the vascular system. The lymphatic system represents one of the
chief components of the immune system, filtering potential immunogens from the
extracellular space. The lymphatic system is not easily accessible by conventional modes of
chemotherapeutic delivery, thus limiting the drug that reaches the lymphatic tissues.
Discoveries in the past decade relating to lymphatic development and vessel growth
(lymphangiogenesis) have provided new insights into the roles of lymphatic development
and function in cancer progression.[1] Therefore lymphatics have been exploited as a
potential route for the delivery of biologically active molecules.
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The lymphatic system is active in the metastatic spread of cancer and dissemination of
infection. The regional lymph nodes, once invaded by tumor cells, act as a reservoir where
cancer cells take root and seed into other parts of the body. However, due to the complexity,
peculiar nature and anatomy of the lymphatic system, localization of drugs in the lymphatics
is difficult. The recent findings by the Laakonen et al. have demonstrated that the tumor
lymphatics carry specific markers that may be utilized to specifically target
chemotherapeutics to the tumor lymphatics.[2] Various modes of drug delivery have been
documented in the literature ranging from emulsions to nanoparticle capsules, which are
complimented by various routes of administration including intramuscular, subcutaneous,
oral and intraperitoneal.
2. Lymphatic Imaging
There is signifincant interest in the development of imaging methods to accurately map the
drainage of solid tumors through the lymph nodes, specifically the sentinel lymph node
(SLN).[3] The sentinel lymph node is considered the first lymph node or group of nodes
reached by metastasizing cancer cells from the solid tumor, and the probability of finding
the metastatic tumor cells is more likely compared to other lymph nodes. Cabanas et al in
the year 1977 introduced the term sentinel node for the first time based on his work on
penile cancer.[4] Since then, mercury injections, dyes and radioactives isotope have all been
employed to visualize the lymphatic drainage of solid tumors.
Numerous clinical studies have emerged in last 10 years validating of the use of the sentinel
node mapping in cancer staging and treatment. Morton et al reported in 1992 on the
development of lymphatic imaging for the mapping of early stage melanoma using vital
dyes, assuming in their studies that the sentinel node was primarily responsible for the
dissemination of metastatic disease[5]. Giuliano et al quickly extended the use of vital dyes
for breast cancer, reporting the first use of dyes for mapping lymphatic metastasis in breast
cancer.[6] Turner et al in 1997 examined whether the sentinel node is required for
dissemination of auxiliary metastasis in breast carcinoma.[7] They showed that if the sentinel
node is free of cancer cells as determined by hematoxylin and eosin staining (H&E) and
cytokeratin immunohistochemical staining (IHC), the probability of nonsentinel node
involvement is less than 0.1 %, clearly demonstrating that the status of the sentinel lymph
node is highly predicative of metastatic potential in breast carcinoma.
2.1 Non Invasive Techniques
Due to the complex and tortous morphology of the lymphatic system, it is a challenge for the
physician to assess the pathology of the lymph system. For long time, the bipedal
lymphography was the primary imaging technique for imaging lymphatics. However the
advancement in the non-invasive techniques such as ultrasound (US), computer tomography
(CT) or magnetic resonance imaging (MRI), fluoresence imaging has enabled the accurate
evaluation of lymph nodes.[3e] These techniques have been enhanced by advancements in
contrast angents for lymphatic imaging. Newer contrast agents are relatively non toxic
compared to the first generations and exhibit high contrast with high site specificity even at
very low concentrations.
2.1.1 Lymphoscintigraphy—Lymphoscintigraphy is a nuclear imaging method that uses
radionuclide injections to obtain information about the lymphatic drainage.
Lymphoscintigraphy is generally performed by subcutaneous injection of radiolabelled
agents such as 99mTc-Labeled dextran,[8] 99mTc-Labeled human serum albumin[9] or 99mTc-
Labeled sulfur colloid[10] that emit gamma rays. The main limitations associated with the
lymphoscintigraphy are poor spatial resolution not allowing determination of the exact
anatomic location of sentinel nodes and the short half-life of 99mTc (6.01 hours) that
Nune et al. Page 2













necessitates onsite generation capabilities. To overcome the drawbacks associated with
tradition lymphoscitigraphy, hybrid SPECT/CT imaging has been developed to obtain
images with better contrast and resolution.[11] However, for routine preoperative sentinel
biopsy, hybrid SPECT/CT is limited by the high associated cost.
2.1.2 Computer Tomography—X-ray computer tomography (CT), is a commonly used
diagnostic imaging tool offering broad availability and relatively modest cost. X-ray CT is
used to visualize tissue density differences that provide image contrast by X-ray attenuation
between soft tissues and electrondense bone. It is desirable to enhance the contrast of
diseased tissue with the use of X-ray contrast agents to increase the contrast between normal
and cancerous tissue.[12] CT is a diagnostic method that is routinely performed to identify
tumors prior to surgery for various cancers such as breast cancer. CT lymphography with
excellent spatial and temporal resolution is commonly used to visualize the tumoral status
and lymphatic drainage pathways. Currently, highly water soluble small organic iodinated
molecules (e.g. iopamidol, ioversol, iohexol, and ioxaglate) are typically used as CT contrast
enhancers for sentinel node imaging. Exposure of the patient to the ionizing radiation and
the limited ability to obtain real time images remain significant challenges associated with
this technique. Sentinel lymph node mapping using CT is primarily based on discerning
anatomic characteristics such as size.
Suga et al investigated the use of computed tomographic lymphography (CT-LG) using the
low molecular weight iodinated constrast agent iopamidol for visualizing breast lymphatic
pathways.[13] Breast tumors are considered to disseminate through the lymphatic system,
and the tumoral status of the sentinel node is reflective of the entire lymphatic system. In
Suga’s study, 0.5 and 1 mL of iopamidol were injected subcutaneously into 10 female
dogs.[13b] By using CT, they were able to clearly visualize the direct connection of the
sentinel node (first lymph node) and the lymphatic vessels with a maximum CT attenuation
of 269±137 HU, even with 0.5 mL of iopamidol. They also performed CT-LG with 2 mL of
iopamidol in five female volunteers, resulting in the localization of iopamidol in the sentinel
node with a maximum attenuation of 269±137. The authors did not observe any significant
adverse effects. Encouraged by these results, they also investigated the ability of CT to
correctly localize the sentinel nodes by injecting 17 pateints with 2 mL iopamidol into
peritumoral and periareolar areas (Fig 1).[14]. For comparison peri-operative blue-dye
injections were also performed. The preoperative CT-LG provided accurate mapping of
sentinel node and further drainage by the visualization of direct connection between a
sentinel node and its afferent lymphatic vessels.
Recently, Takahashi et al studied the identification of sentinel nodes in breast cancer
patients using subcutaneous injections to the tumor, the areola, or both, with CT-LG.[15] The
sentinel nodes were correctly identified in 212 of 221 procedures (96 %) using CT-LG
whereas dye-guided procedures yielded an idenfication rate of 92 % (202/219). They also
compared the combined identification of sentinel nodes in breast cancer using CT-LG and
the dye-guided method, and they investigated the relationship between sentinel node
identification rates and clinicopathological findings. CT-LG, the dye-guided method, and the
combined modalities showed no differences as a function of age, menopausal status, tumor
diameter, or histopathological type. However, they found that identification rates were lower
in the case of the dye-guided method in patients with a body mass index BMI of 25 or more,
whereas the CT-LG and the combined methods were not influenced. The results obtained by
Takahashi et al on the use of the combined method (CT-LG and dye-method) of
identification of sentinel nodes in breast cancer are corroborated by a study conducted by
Wu et al on the identification of sentinel lymph nodes in the tounge VX2 carcinoma
model.[16] The main concern with the use of highly water soluble small organic iodinated
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molecules as CT contrast enhancers is they tend to suffer from very short imaging times due
to rapid renal clearance and non-specific vascular permeation.
2.1.3 Magnetic Resonance Imaging (MRI)—MRI is one of the most powerful
noninvasive medical imaging techniques that is commonly used in clinical medicine. MRI is
used to visualize the structure and health of tissues, and generally provides increased
contrast between soft tissues compared to computer tomography (X-ray CT). MRI is based
on the behavior, alignment and interaction of protons in the presence of an applied magnetic
field. Within a strong magnetic field, protons in the tissue are perturbed from B0; contrast
agents are used to alter longitudinal (T1) or transverse (T2) relaxation times, which can be
monitored by MRI. Contrast agent efficiency is determined by its relaxivity over a range of
concentrations. Unlike radionuclide-based imaging, MRI eliminates the radiation dose and
can offer higher spatial resolution.
Various contrast agents including nanoparticles have been developed to improve contrast in
MRI imaging of lymphatic system;[17] these include, gadolinium based agents such as
gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA), various iron oxide
nanoparticles, and liposomes and dendrimers containing Gd(III) /or iron oxides. Significant
benefits associated with iron oxide nanoparticles are their biocompatibility and ready
detection at moderate to low concentrations. Super paramagnetic iron oxide nanoparticles
(SPIONs) have a high saturation magnetization and loss of magnetization in the absence of
magnetic field, and these nanoparticles are perceived to be relatively less toxic than optical
imaging agents such as quantum dots.[18] Peptides, antibodies, proteins, and small molecules
have been conjugated to SPIONs and cross linked iron oxide (CLIOs) for active targeting
(REFs). Wunderbaldinger et al. used dextran-SPION to detect lymph node metastases in an
experimental murine model using contrast-enhanced MRI.[19] Ultra small
superparamagnetic iron oxide (USPIO) (Sinerem, Combidex, Clariscan) are particles with
median diameter less than 50nm have been used as MRI contrast agents that may improve
the ability of Magnetic Resonance Imaging (MRI) to see lymph nodes. USPIO nanoparticles
have long serum half-lives, which is very important for systemic lymph node imaging.[20]
The non-magnetic nature of USPIO in the absence of an external field benefits their use for
imaging fine structures such as the lymphatics, as magnetism induced agglomeration is
avoided.
Harisinghani et al investigated the use of highly lymphotropic superparamagmetic
nanoparticles as contrast enhancers for noninvasive high resolution MRI detection of lymph-
node metastasis in prostate cancer.[21] In a study of 33 patients, MRI images obtained in
patients injected with lymphotropic superparamagmetic nanoparticles as contrast enhancers
(2.6 mg of iron per kilogram of body weight) identified patients with nodal metastases with
significantly higher sensitivity than conventional MRI (90.5 % vs. 35.4 %) and with
improved diagnostic specificity 97.8 %. [21] Ross et al also successfully identifed lymph
node metastases in prostate cancer using an intravenous infusion of ferumoxtran-10 (2.6 mg
Fe/kg), a constrast agent specific to the lymph nodes.[22] Heesakkers et al further studied
lymph node metastases in patients with prostate cancer outside the routine pelvic lymph
node dissection area with enhanced MR-imaging using ferumoxtran-10 as contrast
enhancer.[23] In their studies in patients having histopathological conformation of lymph
node metastasis, MR lymphography images predominantly demonstrated the nodes outside
the routine pelvic lymph node dissection over the CT-guided biopsy. Harisinghani et al in
his recent findings reported that the use of ferumoxtran-10 as contrast enhancer with a
sensitivity of 100 % and the specificity of 96% in patients with nodal involvement in
prostate cancer.[24] Bellin et al reported the use of USPIO for malignant lymph node
detection in 30 patients with urological and pelvic cancers with a sensitivity of 100 % and
80 % selectivity with no adverse side-effects.[25] Guimaraes et al recently reported the
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sensitivity of 100 % and specificity of 95.7 % in 9 patients accessing lymph nodes in renal
cell cancer using ferumoxtran-10 (Combidex).[26]
Axillary lymph node status has proven to be one of the most prognostic factors in breast
cancer staging and survivorship. [27]The nodes are currently evaluated by surgical dissection
followed by microscopic histological and immunohistological evaluation, which is
destructive and can lead to serious complications. Murray et al used dynamic gadopentetate
dimeglumine (Gd) enhanced MRI for non-invasive staging of the axillary lymph nodes in 47
women with a new primary breast cancer. Enhancement indices and nodal area were
compared with histopathology of excised nodes. MRI images of axillary lymph node
revealed the enhancement index of >21% and a nodal area of >0.4 cm2 in 10 patients having
auxillary metastases confirmed pathologically with a sensitivity of 100%, although the
specificity was only 56 %.[28] Michel et al studied preoperative assessment of breast axillary
lymph nodes by MR imaging using ultrasmall superparamagnetic iron oxide (USPIO) in 20
patients.[29] No serious adverse effects occurred in patients given a slow drip infusion (2.6
mg of iron per kilogram of the body weight, diluted to 100 ml saline]. A recent study by
Kimura et al used USPIO lymphography to differentiate normal and diseased nodes by
enhancement patterns based on the T2*-weighted and T1-weighed images.[30]
2.1.4 Optical Imaging—Optical imaging has the benefits of being non-invasive with good
resolution at shallow depths and does not require any radiation exposure. Although various
probes have been used in the sentinel lymph node optical imaging, this review emphasizes
the use of quantum dots. Quantum dots (QDs) are fluorescent semiconductor nanocrystals (1
to 100 nm) with unique optical and electrical properties.[31] Compared to organic dyes and
fluorescent proteins, QDs possess near-unity quantum yields and much greater brightness
than most dyes (10–100 times). QDs also exhibit broad absorption characteristics, a narrow
line width in emission spectra, continuous and tunable emission maxima due to quantum
size effects, a relatively long fluorescence lifetime (5 to > 100 ns compared to 1–5 ns for
organic dyes), and negligible photobleaching over minutes to hours (100–1000 times less
than most fluorescent dyes). Synthetic techniques exist for the precise control of QD size
and composition, which in large part control the absorption and emission characteristics.
Furthermore, the surface of QDs can be functionalized with polyethylene glycol and other
polymeric coatings that allow targeting and avoidance of macrophage clearance.[32] This can
allow researchers to exploit QDs’ unique properties for applications such as cell labeling,
biosensing, and nucleic acid detection. QDs are increasingly used as fluorophores for in vivo
fluorescence imaging.[33] Fluorescence imaging has several advantages compared to other
imaging modalities since this method has good sensitivity and is non-invasive in nature
using readily available and relatively inexpensive instruments. Also, fluorescence imaging
has high resolution and sensitivity compared to radiotracers and dye absorption. A wide
variety of in vivo studies have validated the potency of QDs.
Identification of lymph node drainage using QDs was one of its first applications along with
mapping the reticuloendothelial system. QDs due to its size undergo endocytosis in cells
particularly by macrophages in lymph node leading to the localization of QDs in sentinel
lymph node enabling for fluorescence imaging. One important point to be noted is due to the
localization of QDs at sentinel nodes, QDs may not be very good for mapping lymphatic
drainage distal to the sentinel node. Ballou et al in 2004 studied the localization of four QDs
with different surface coatings and demonstrated that the QDs remained fluorescent for at
least four months in vivo and that the localization of QDs was dictated by the surface
coating.[34] The authors recently extended this technique to mouse tumor models for sentinel
lymph node imaging (Fig 2).[35] They studied the migration quantum dots bearing
differently charged surface groups injected into murine tumor models to map sentinel lymph
nodes. The authors used 655-nm emitting Zns-CdSe and 800-nm emitting ZnS-CdSe-CdTe
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core QDs coated with an amphiphilic polymer having a very high density of surface carboxy
groups, which were further modified with PEGs having terminal methoxy, carboxy, oramino
functional groups; thus, generating PEG containing neutral, positive, and negatively charged
QDs. Their fluorescence imaging studies on mice bearing m21 melonoma and MH-15
teratocarcinoma injected with significantly different sized QDs [hydrodyanamic diameters
(nm); 22.6 (neutral), 30.4 (negative) and 41.2 (positive)] revealed to their surprise that all
three QDs migrate similarly to lymph nodes, and charge and size had no effect drainage to
surrounding lymph nodes.
Recently, Kobayashi used multiple QDs with similar physical sizes but different emission
spectra to perform multispectrum imaging of lymphatic drainage. They employed five
carboxy terminated QDs made of Cd-Se [565, 605, and 655 nm emission peaks] or CD-Te
[705 and 800 nm emission peaks] (Table 1, Fig 3). Using different injection sites for each
QD, they simultaneously visualized five separate lymphatic drainage pathways. This method
has significant advantages over other techniques such as X-ray lymphangiography and MR-
LG or radio nucleotide scintigraphy in cases where multiple drainage basins are examined
simutaneously.[36] Recently Bhang et al developed a stable, size tunable (50–120 nm)
hyaluronic acid-QD conjugate by using a simple electrostatic coupling method. The
conjugates were used to demonstrate the fluorescence staining of lymphatic vessels in vitro
and in vivo.[37] Robe et al reported the use of Cd/Se/Zns core shell QDs emitting around 655
nm for axillary lymph node mapping. Subcutaneous injection of 20 µL of a 1-µm QDs
solution in the anterior paw of healthy nude mice lead to the localization of QDs in the
axillary lymph nodes, with a maximum amount detected after 60 min, 2.42 % of the injected
dose.[38]
Compared with other recently developed techniques for lymphatic imaging, fluorescence
probes offer cost effectiveness, greater speed, and improved sensitivity at least for lymph
nodes that are close enough to the surface to be imaged. For mapping deep nodes, the
combination of QD fluorescence and other non-invasive techniques such as MRI or
radiotracer scintigraphy would give more information about SLN than single techniques
alone, such as 99mTc and dye injections. The use of simultaneous multicolor imaging may be
particularly useful for tumor diagnosis; sentinel nodes could be imaged with non specific
QDswhile and QDs with tumor specific ligands could be used to localize metastases in
lymph nodes. Although the use of QDs for in vivo imaging offer advantages over other
traditional techniques, there synthesis requires heavy metals, which raises questions about
their safety and ultimately may impact their acceptance by regulatory agencies.[18b] [39]
3 Carriers for Lymphatic Imaging and Drug Delivery
There is a significant interest in the development of carrier systems for the targeted
localization of contrast agents at lymph nodes.[40] Various factors such as size, composition,
dose, surface charge, and the molecular weight of carriers influence the uptake by the
lymphatics. For example there is an optimum range for lymphatic uptake of subcutaneously
injected particles; particles greater than 100 nm in diameter will remain largely at the
injection site, and particles between 10–80 nm are taken up well by the lymphatics, while
smaller particles are absorbed by the capillary network that drains into the systemic
circulation.[41] The use of nanocarriers based imaging agents has advantages such as size
tunability and the surface of particles can be functionalized for improved selectivity, which
may decrease toxicity due to less uptake by non-target tissues and organs.
3.1 Dendrimers
Dendrimers are well-defined, highly branched molecules that are synthesized with precise
structural control and low polydispersity.[42] Recently dendrimers have emerged as versatile
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materials for biomedical research applications such as drug delivery and imaging.[43]
Dendrimers are promising materials for the development of imaging contrast agents due to
precise control of their molecular structure, tunable variation in size, availability of a large
number of reactive sites, low viscosity compared to equivalent molecular weight linear
polymers, narrow polydispersity, and interior void space. By taking advantage of the regular
structured nature of dendrimers, many of the obstacles associated with low molecular weight
contrast agents and imprecise synthetic polymers can be overcome. The two major strategies
commonly employed in the synthesis of dendrimers are the “divergent” and “convergent”
methods. The divergent method, introduced by Tamalia et al., begins with a multifunctional
core followed by repeated addition of monomers to increase molecular weight and
exponentially increase surface termini.[44] By contrast, the convergent method pioneered by
Frechet et al. begins from the surface and proceeds inward to a multivalent core where the
dendrimer segments are joined together.[45] Biocompatible water soluble dendrimers such as
polyamidoamine (PAMAM, i.e. Starburst™), internal architectures nearly mimicking the
structure of proteins and peptides, have have gained attention for bio-imaging applications.
The utilization of dendrimer-based contrast agents for dynamic magnetic resonance
lymphangiography was pioneered by Kobayahsi et al in 2003.[46] Gd-containing dendrimers
with different sizes and molecular structures (PAMAM-G8, PAMAM-G4, and DAB-G5)
[PAMAM: polyamido amine, DAB: diaminobutyl] were conjugated with Gd and compared
as constrast agents. Size and molecular structure had large impacts on distribution and
pharmacokinetics. For example, PAMAM-G8 had a relatively long life in the circulartory
system when injected intravenously with minimum leakage out of the vessels, whereas
PAMAM-G4 was cleared rapidly from the systemic circulation due to rapid renal clearance
but had immediate survival in lymphatic circulation. The smaller sized DAB-G5
accumulated and was retained in that lymph nodes, which may be useful for lymph node
imaging using MR-LG. Gadomer-17 and GD-(DTPA)-dimeglumine (Magnevist) were
compared as controls. Imaging experiments revealed that all of the reagents are able to
visualize the deep lymphatic system except GD-(DTPA)-dimeglumine. PAMAM-G8 was
best suited to visualize the lymphatic vessels whereas DAB-G5 was best able to visualize
lymph nodes. The behavior of PAMAM-G4 was in between that of PAMAM-G8 and
DAB-5, providing good contrast of both the nodes and connecting vessels. Gadomer-17 was
able to visualize lymph nodes, but not as clearly as Gd-based dendrimers.
Kobayashi also investigated the delivery of various Gd-PAMAM (PAMAM-G2, G4, G6,
G8) and DAB-G5 dendrimers to the sentinel lymph nodes and compared its visualization
with other nodes.[47] The G6 dendrimer was found to be absorbed and retained in the
lymphatic system and was able to provide excellent opacification of sentinel lymph
nodes.[47] Talanov et al recently introduced the bifucntional dendrimers-based nanoprobe
for dual modality magnetic resonance and fluorescence imaging (MR-FI).[48] PAMAM
dendrimers were covalently conjugated to GD-DTPA chelates and the NIR fluorescent dye,
Cy 5.5. To our knowledge this is the first dual imaging probe that provides excellent spatial
resolution of MRI with very high sensitivity of fluorescence. Using G6-PAMAM-Gd-Cy the
sentinel nodes were more clearly observed using a combination of MRI and fluorescence
demonstrating the potential of the dendrimers as platform for dual imaging. For consistent
visualization of the sentinel lymph nodes, 25 mL of 30 mM Gd-G6PAMAM-Cy 5.5 (750
nmol based on Gd) was required. The low sensitivity associated with MRI imaging by Gd-
G6PAMAM necessitates high doses of contrast agent, and the early QD studies used
fluorophores with limited depth penetration and potential heavy metal toxicity., Kobayashi
et al further extended the simultaneous use of two modalities (radionuclide and optical
imaging) to overcome the sensitivity limitation and depth limitations of with each individual
method. They developed multimodal nano probes for radionuclide and multicolor optical
lymphatic imaging using G6-PAMAM dendrimers conjugated with near infared (NIR) dyes
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and an 111In radionuclide probe[49]. In the head and neck region of mice, the radionuclide
provided semi-quantitative information of delivery whereas the optical probes provided the
qualitative information with excellent spatial resolution. Kobayashi further proposed the use
of two nanomaterials for multicolor imaging of lymphatic system -- quantum dots for
labeling cancer cells and dendrimer based optical agents for visualization of lymphatic
drainage and identification of sentinel lymph nodes.[50] Based on the developments, it is
very apparent that no imaging modality is perfect; every method has its own advantages and
limitations on the visualization of complex lymphatic system.
Polylysine coated dendrimers have been used to target the lymphatic system and lymph
nodes. Porter and co-workers demonstrated that PEGylated poly-L-lysine dendrimers are
well absorbed from subcutaneous injection sites and that the extent of lymphatic transport
may be enhanced by increasing the size of the PEGylated dendrimer complex. They
evaluated the lymphatic uptake and lymph node retention properties of several generation
four dendrimers capped with PEG or 4-benzene sulphonate after subcutaneous
administration in rats. Three types of PEGs with molecular weights of 200, 570, or 2000 Da
were used for the surface modification. PEG200 derived dendrimers were quickly and
completely absorbed into the blood when injected subcutaneously and only 3% of the
administered dose was observed in the pooled thoracic lymph over 30 hrs. Absorption of
PEG570 and PEG 2000 derived dendrimers in blood was low and a higher amount was
recovered in lymphatics (ca. 29%) over 30 hrs. After intravenous administration, indirect
access to the lymph was observed for PEG 570 and PEG 2000 because of equilibration
across the capillary beds with the lymph. However, the benzene sulphonate capped
dendrimer was not well absorbed either in blood or in lymph following subcutaneous
inejction.[51]
3.2 Polymeric Carriers
Numerous polymeric particles have been synthesized for targeted and sustained drug
delivery. The polymers are either natural polymer like Dextran, alginate, chitosan, gelatin
and Hyaluronic acid or synthetic polymers like PLGA, PLA and PMMA.
3.2.1 Natural Polymers—Owing to its excellent biocompatibility, dextran has been used
as a carrier for drug molecules, peptides, proteins and enzymes. Kim et al reported the
synthesis of Cyclosporine A loaded dextran acetate particles labeled with 99mTc. These
particles were prepared by reacting dextran with acetic anhydride followed by Cyclosoprine
A loading. Upon subcutaneous injection into the foot pad of rats, these particles steadily
distributed Cyclosporin A as well the 99mTc label throughout the lymph nodes.[52] A
lymphotropic delivery system has been reported for mitomycin C by conjugating it to
dextrans with average molecular weights of 10, 70, and 500 kDa. Following intramuscular
injection in mice, the mitomycin C-dextran conjugates (MMC-D) were retained at the
injection site for a longer period compared to free mitomycin C. Moreover, there was a
significant accumulation of MMC-D in regional lymph nodes which persisted for nearly 48
h while the free mitomycin was rapidly cleared. The in vivo effect of MMC-D on lymph
node metastasis was evaluated using a metastatic leukemia L1210 model in mice. There was
a significant effect on the weight of lymph nodes when mice were treated with a 2.5 mg/kg
dose of MMC-D (70 and 500 kDa) four days post-tumor inoculation, while free MMC and
MMC-D (10 kDa) did not exert any effect.[53]
Hyaluronic acid, an anionic non-sulfated glycosaminoglycan, is a biocompatible polymer
that follows lymphatic drainage from the interstitial spaces. Cai et al synthesized a cisplatin
hyaluronic acid conjugate for intralymphatic delivery of the drug. Upon subcutaneous
injection into the upper mammary fat pad of female rats, the conjugate resulted in a
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significant increase in the drug concentration in the local regional nodal tissue above the
standard cisplatin formulation. Cisplatin-HA conjugates were well tolerated in rats without
any major organ toxicity after 96 hrs. The conjugate also exhibited sustained release kinetics
which would in turn lead to into lower organ over time.[54] The hyaluronate (HA) receptor
has been used to deliver anticancer drugs selectively to lymph nodes and tumors. To
investigate the specific distribution of HA into regional lymph nodes and to evaluate the HA
receptor on lewis lung carcinoma cells, 14C-labelled HA and fluorescent HA (FR-HA) were
synthesized, along with drug conjugates HA-mitomycin C and HA-epirubicin. Upon s.c
administration of 14C-HA and HA-epirubicin, distribution of both compounds was observed
in the lymph nodes. Cellular internalization studies showed that FR-HA was entered into the
cells via CD44 receptors. When HA-mitomycin C (MMC) was injected into lewis lung
carcinoma implanted mice at a low dose of 0.01 mg/kg, anti-metastasis effects were
observed, whereas free MMC had no effect on metastasis in the same model.
3.2.2 Synthetic polymers—Biodegradable nanospheres of poly(lactide-co-glycolide)
have been reported to deliver drugs and diagnostic agents to the lymphatic system. Sub-100
nm nanospheres were coated with block co-polymers of poloxamers and poloxamines, along
with radiolabelled 111In-oxine to trace the nanoparticles in vivo. Uptake of the block
copolymer coated nanospheres in the lymphatic system was higher in comparison with the
uncoated system upon s.c. injection. Moreover, a maximum uptake of 17% of the
administered dose was observed in the regional lymph node.[55] Dunne et al used a
conjugate of cis-diamminedichloro-platinum(II) (CDDP) and poly(ethylene oxide)-block-
poly(lysine) (PEO-b-PLys) block copolymer for the treatment of lymph node metastasis.
When VX-2 tumor bearing animals were treated with high drug-loaded (48 wt% CDDP)
polymers, it resulted in 90% of the animals being cured. Limited tumor growth in the
draining lymph nodes and prevention of systemic metastasis was observed with one animal
treated with 10 wt% CDDP- polymer.[56]
Efficient delivery of anti-cancer agents to the lymph nodes or lymphatic vessels where
tumor cells may metastasize is important to curb early and occult disease. Johnston and
coworkers designed a biodegradable intrapleural (ipl) implantable drug delivery system
consisting of a gelatin sponge impregnated with polylactide-co-glycolide paclitaxel (PLGA-
PTX) to target thoracic lymphatics. This system showed sustained drug release properties in
vitro and exhibited lymphatic targeting capability in rat models. Three types of formulations,
a paclitaxel solution, PLGA-PTX microspheres, and a PLGA-PTX sponge were used to
study the pharmacokinetics. For ipl sponge implantation, the PLGA-PTX sponge was placed
into the pleural space through a left thoractomy. Substantial lymphatic drug exposure was
observed (>400 fold) when PLGA-PTX (equivalent to Taxol 7 mg/kg) microspheres and
PLGA-PTX (Taxol 7 mg/kg) sponges were placed within the pleural cavity compared to
paclitaxel solution (Taxol 8 mg/kg) injected by iv or ipl. Histological experiments revealed
the presence of these PLGA-PTX microspheres in lymphatic tissues upto 4 weeks after the
sponge was implanted. The therapeutic effect of these particles was studied in an orthotopic
lung cancer model with tumor resection 14 days post tumor cell implantation. Lymph node
metastasis was examined in the animals after 32 days following ipl placement of the PLGA-
PTX sponge, placebo sponge, or no treatment. The incidence of lymphatic metastasis and
tumor burden was significantly lower in the treatment group compared with that of the non
treatment controls and placebo sponge controls. Thirty-two of a total of 40 lymph nodes
(80%) obtained from control animals (28 from no treatment controls and 12 from placebo
sponge controls) were found to contain tumor metastases. Four of 26 lymph nodes (15.4%)
from the treatment group showed tumor involvement, all of which were in the contralateral
mediastinum.[57] Kumanohoso et. al developed a new drug delivery system by loading
bleomycin (BLM) into a small cylinder of biodegradable polylactic acid (PLA) to target
lesions. Bleomycin was continuously released for more than 3 weeks from the polymer in
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saline. A higher concentration of BLM was observed in abdominal lymph nodes following
s.c. implantation of BLM-PLA was than a s.c. injection of BLM-soln. Further, the anti-
tumor effect of BLM-PLA was significantly higher compared to BLM-soln and no
treatment.[58]
A new system for the delivery bleomycin (BLM) to target lesions was established by
incorporating BLM into a small cylinder of a biodegradable colloidal particulate based
nanoparticle carrier system to target thoracic lymphatics and lymph nodes. The lymphatic
distribution of various nano and micro particles of charcoal, polystyrene; and poly(lactide-
co-glycolide) was investigated after intrapleural implantation in rats. All three types of
particles were cleared by regional thoracic lymphatic system following injection into pleural
space. The lymphatic uptake was observed as early as 3 hrs after injection mainly through
the parietal pleura. The most extensive lymphatic distribution was observed for particles of
size 0.7–2 microns. One possible explanation given by the authors for the low uptake of
small particles in lymph nodes is that, even though these particles may have easy access to
pleural lymphatics, they fail to be retained in regional lymph nodes.[59]
3.3 Miscellaneous Carriers for Lymphatic Drug Delivery
Because of their unique mechano chemical properties, carbon nanotubes (CNT) are being
investigated as drug carriers. They have a high surface area, mechanical strength, thermal
and chemical stability making them versatile carriers for drugs, proteins, radiologicals, and
peptides to target tumor tissues. Hydrophilic multi-walled carbon nanotubes (MWNT)
decorated with magnetic nanoparticles (MN-MWNT) have been used to target the lymphatic
system. MN-MWNTs were obtained by chemical co-precipitation of Fe2+ and Fe3+ onto the
outer surface of polyacrylic acid grafted MWNTs (PAA-g-MWNTs). Upon subcutaneous
injection of these particles into the left footpad of Sprague Dawley rats, the left popliteal
lymph nodes were dyed black as early as 3 hrs after administration. Moreover, no uptake
was observed in major internal organs such as the liver, spleen, kidney, heart, and lungs,
throughout the whole course of the experiment, suggesting the preferential absorption of
MN-MWNTs by lymphatic vessels and their subsequent transfer into lymph nodes.
Lymphatic delivery efficiency of these particles was evaluated by loading them with
gemcitabine (GEM). The animals were randomized into 5 groups: GEM without drug carrier
and external magnetic field (GEM-Control); GEM loaded MN-MWNTs with external
magnetic field (MN-MWNTs-GEM-Magnet), GEM loaded MN-MWNTs without magnetic
field (MN-MWNTs-GEM), GEM loaded in MN-ACs (nano-sized activated carbon
decorated with magnetic nanoparticles), GEM loaded in MN-ACs with magnetic field (MN-
ACs-GEM-Magnet), and GEM loaded in MN-ACs without magnetic field (MN-ACs-GEM).
The MN-MWNTs-GEM-Magnet group exhibited the highest concentration of gemcitabine
in the lymph nodes throughout the experiment. A significant difference (P < 0.01) between
MN-MWNT’s and other control groups was observed at 6, 12, 24 and 192 hrs. Furthermore,
MN-MWNTs showed a higher gemcitabine delivery efficiency than MN-ACs, especially
when an external magnetic field was applied, which aggregated the MN-MWNTs at a
specific location. In addition, the plasma concentration of gemcitabine distinctly decreased
when loaded into MN-MWNTs.[60] McDevitt et al synthesized tumor-targeting CNT
constructs by covalent attachment of multiple copies of tumor-specific monoclonal
antibodies, radiometal-ion chelates, and fluorescent probes to sidewall-functionalized,
water-soluble CNTs. The antibodies used were Rituximab and Lintuzumab. DOTA was used
as a metal ion chelator while the fluorescent probe was fluorescein. CNT-([111In]DOTA)
(Rituximab) specifically targeted a disseminated human lymphoma in vivo experiments
compared to the controls CNT-([111In]DOTA)(Lintuzumab), and [111In]Rituximab.[61]
The drug delivery efficiency of water-dispersed carbon nanohorns in a nonsmall cell lung
cancer model has been evaluated by Tsuchida and coworkers. These nanohorns were
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prepared by adsorption of polyethylene glycol-doxorubicin conjugate (PEG-DXR) onto
oxidized single-wall carbon nanohorns (oxSWNHs). Intratumoral injection of PEG-DXR-
bound oxSWNHs into mice bearing human non small cell lung cancer (NCI-H460) resulted
in significant retardation of tumor growth. Histological analyses revealed migration of
oxSWNHs to the axillary lymph node, which is a major site of breast cancer metastasis near
the tumor, possibly by means of interstitial lymphatic-fluid transport.[62] Shimada et al
reported a silica particle based lymphatic drug delivery system for anti-cancer agent,
bleomycin. The drug was adsorbed on the surface of small silica (SI) particles and its
therapeutic efficacy as compared to that of free bleomycin solution in a transplanted tumor
model in animals. The inhibitory effect on tumor growth and lymph node metastasis was
remarkable for Si particle adsorbed bleomycin compared to with free BLM solution.[63]
Activated carbon particles have been used for adsorption and sustained release of
aclarubicin (ACR-CH) into lymph nodes. ACR-CH resulted in significantly higher
distribution of aclarubicin to the auxiliary lymph nodes compared to aqueous solution of the
drug (ACR-sol) after subcutaneous administration into the fore foot-pads of rats. A lower
uptake of aclarubicin was observed in other tissues with ACR-CH.[64] Activated carbon
particles have also been used by another group for adsorption of aclacinomycin A,
adriamycin, mitomycin C, and pepleomycin. Animal experiments demonstrated that the
LD50 values for these carbon particle adsorbed drugs were higher than those of the drugs in
solution. In addition, the lymph node concentration of the drugs was also maintained at a
higher level in the new dosage form than in the solution form.[65]
4. Conclusion
The lymphatics lay a major role in the progression of cancer and the function of the immune
system, and their proper function is crucial to health. The development of drug delivery
systems and imaging agents that can directly treat disease advanced into the lymphatics and
gauge the response to treatments in these tissues will improve patient diagnoses and
treament. Lymphatic imaging has proven very important in the staging of cancers, and new
imaging tools are making this a much less invasive process by reducing or eliminating the
need for biopsies and unnecessary removal of healthy nodal tissue. In addition, newer
imaging agents provide higer resolution and less risk to patients due to radiation and
toxicity. Drug delivery to the lymphatics is in its infancies, but initial trials in animal models
have show the tremendous potential this route of delivery has for the control and
containment of early stage cancers. In summary, although lymphatic drug delivery and
imaging will not replace systemic chemotherapy and more generalized tissue imaging tools,
drug delivery and imaging agents designed specifically for the lymphatics will complement
and enhance existing tools for the treament of cancer patients.
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CT image illustrating the lymphatic pathways enhanced with injected iopamidol.[14]
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Fluorescent imaging lymphatic drainage after injection of fluorescent QDs into mice bearing
M21 melanoma. Left frames A,C,E: channel after tail vein injection of PEG 5k-COOH
coated QDs; right frames B,DE: 800-nm channel after intratumoral injection of PEG 5k-
OMe coated QDs.[35]
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Illustration of simultaneous multicolor imaging of lymphatic drainage[36a]
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